PEOPLE - Ceapro makes appointment:
This article was originally published in Clinica
Edmonton, Alberta-based Ceapro has appointed Oleh Hnatiuk as acting managing director of its Ceapro Technology subsidiary. He will have supervision of the commercial activities relating to AccuScreen, the group's type 2 diabetes early detection test. Mr Hnatiuk is president of technology commercialisation advisory company Connect Capital Corp and was formerly president of University Technologies International. His skills and experience in networking will be employed at a critical time for the commercial introduction of AccuScreen, said Ceapro president and CEO Dr Mark Redmond.
You may also be interested in...
Keytruda is set to remain dominant despite knockback, though Tecentriq could claim prized NSCLC adjuvant approval first
Vertex is hoping for EU approval in Q4 of its cystic fibrosis triple combination therapy, Trikafta. It wants the same licence in the EU as it has in the US, where the product has already become a best seller for the company.